Clinical Research Directory

Inclusion Criteria: * Patients with primary myelofibrosis or myelofibrosis secondary to myeloid tumors were diagnosed according to the diagnostic criteria of who 2022. * Stable vital signs, ECOG score ≥ 2 points, tolerate and cooperate to complete 18F-FDG PET/CT and 18F-FAPI PET/MRI examination. * The interval between imaging ,hematologic, cytogenetic and pathology was \< 2 weeks. * Willing to accept 18F-FDG PET/CT and 18F-FAPI PET/MRI , sign the informed consent. Exclusion Criteria: * Inability or unwillingness to provide informed consent. * Other malignancies, autoimmune diseases, or chronic active infections were diagnosed within 1 year before the diagnosis of myelofibrosis. * Current infection was present within 1 week before PET examination. * Pregnant or lactation. * Unable to follow protocol to complete follow-up. * Have received glucocorticoid therapy within 2 weeks before PET imaging examination. * Using granulocyte colony-stimulating factor (G-CSF) within 4 weeks prior to PET imaging.